Functional analyses of target proteins and biomarkers
Cancer as well as neurodegenerative and psychiatric disorders belong to the most common diseases. We employ a broad spectrum of molecular biological methods to identify and validate new drug targets and biomarkers for cancer and for diseases of the nervous system.
High-throughput RNAi technology is used to identify candidate target genes on a genome-wide scale. Hits are then validated in detail in vitro, using cellular assay systems, or in vivo.
State-of-the-art molecular biological methods enable the identification of differentially regulated biomarkers and target proteins associated with cancers or with diseases of the nervous system